Abstract
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of psoriatic disease. This review summarizes the current data regarding the use of infliximab in treating psoriasis and psoriatic arthritis, as well as the safety data available from patients with other immune-mediated inflammatory disorders. Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
